Home » Health professionals » Recommendations » Selected literature

Selected literature

  1. Grey A, Bolland MJ, Wattie D et al. The antiresorptive effects of a single dose of zoledronate persist for two years: A randomised placebo-controlled trial in osteopenic postmenopausal women. J Cili Endocrinol Metab 2009: 94:538.
  2. Bolland M, Grey A, Horne A. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res 2008: 23:1034.
  3. Wells GA, Cranney A, Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008: CD001155 National Osteoporosis Foundation (NOF) (January 2010 revision) Physician’s Guide to Prevention and Treatment of Osteoporosis.
  4. Dawson-Hughes B, Heaney RP, Holick M, Lips R, Meunier P, Vieth R (2005) Estimates of optimal Vitamin D status. Osteoporosis Int 16:713-716.
  5. Mark R Forwood (2000) Exercise Recommendations for Osteoporosis: A position statement of the Australian & New Zealand Bone & Mineral Society. Australian Family Physician 29(8):761-764.
  6. Australia & New Zealand Bone & Mineral Society (September 2006): Calcium & Bone Health – Draft position paper.
  7. National Osteoporosis Foundation (July 2007) Updated Recommendations for Calcium and Vitamin D Intake.
  8. Australia & New Zealand Bone & Mineral Society: Vitamin D & Bone Health in Australia & New Zealand, Position Statement.
  9. Black D, Delmas P, Eastell R, Reid I R, Boonen S, Cauley J, Cosman, F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Huilin H, Caminis J, Tong K Rosario-Jansen T, Krasnow J, Hue T, Sellmeyer D, Eriksen E F, Cumming S, for the HORIZON Pivotal Fracture Trial (May 2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEMJ 356(10):1809-1822.
  10. Risks & Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomised Controlled Trial. JAMA 288(3):321-333, 2002.
  11. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women’s Health Initiative Randomised Controlled Trial. JAMA 291(4):1701-1712, 2004.
  12. Siris, et al (Sep 2005) Skeletal Effects of Raloxifene after Eight Years: Results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20(9):1514-24.